Trastuzumab Agents
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0166 alerts
Get alerted when Policy CC-0166 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and clinical review, including prior authorization and step therapy, for Herceptin, Herceptin Hylecta, and specified trastuzumab biosimilars used for HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.
The policy was revised on 09/01/2026 with updates to the trastuzumab step therapy table.
The 09/01/2026 policy update revised the step therapy table.
Hercessi was added to prior authorization and step therapy criteria in the 06/10/2024 select review.
Step therapy for the Medicaid line of business was added on 12/21/2020.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.